MDA5 variants trade antiviral activity for protection from autoimmune disease

Chris Wallace[1,2,*], Rahul Singh[1,3], Yorgo Modis[1,3,*]

[1]Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge CB2 0AW, UK

[2]MRC Biostatistics Unit, University of Cambridge, Cambridge CB2 0SR, UK

[3]Molecular Immunity Unit, Department of Medicine, University of Cambridge, MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK

*Correspondence: C.W., cew54@cam.ac.uk; Y.M., ymodis@mrc-lmb.cam.ac.uk

Running title: MDA5 variants offer a fitness trade-off

Abstract

Loss-of-function variants in MDA5, a key sensor of double-stranded RNA from viruses and retroelements, have been associated with protection from type 1 diabetes (T1D) in genome-wide association studies (GWAS). MDA5 loss-of-function variants have also been reported to increase the risk of inflammatory bowel disease (IBD). Whether these associations are linked or extend to other diseases remains unclear. Here, fine-mapping analysis of four large GWAS datasets shows that T1D-protective loss-of-function MDA5 variants also protect against psoriasis and hypothyroidism, while increasing the risk of IBD. The degree of autoimmune protection and IBD risk were linearly proportional. The magnitudes of the odds ratios for autoimmune protection and IBD risk were larger for rare MDA5 variants than for common variants, which were differentially expressed in different geographic populations. Our analysis suggests MDA5 genetic variants offer a direct fitness trade-off between viral clearance and autoimmune tissue damage.

Keywords: human genetic variants / genome-wide association studies (GWAS) / autoimmune disease / inflammatory bowel disease (IBD) / fitness trade-off

Introduction

Innate immune responses must be sensitive enough to detect infection yet specific enough to avoid activation by cellular components. A key innate immune receptor for cytosolic double-stranded RNA (dsRNA), a potent signature of viral infection, is MDA5 (Berke & Modis, 2012; Kato *et al*, 2006; Peisley *et al*, 2011; Yu *et al*, 2021; Yu *et al*, 2018). Recognition of dsRNA by MDA5 induces a potent IFN-β response (Berke & Modis, 2012; Peisley *et al*., 2011). The ATPase activity and dsRNA binding cooperativity of MDA5 confer the necessary sensitivity and specificity of MDA5-dsRNA recognition (Singh *et al*, 2024b; Yu *et al*., 2021; Yu *et al*., 2018). Mutations in the gene encoding MDA5, *IFIH1*, can

perturb the balance between sensitive and specific dsRNA recognition. *IFIH1* is a hotspot for natural variants with clinical associations. Approximately 40 gain-of-function missense variants have been associated with interferonopathies (Rice *et al*, 2020; Rodero & Crow, 2016; Rutsch *et al*, 2015). These variants promote formation of MDA5 signaling complexes, including on endogenous dsRNAs, by either increasing the RNA binding affinity of MDA5 or inhibiting its ATP-dependent proofreading activity (Garau *et al*, 2019; Rice *et al*., 2020; Yu *et al*., 2021). Loss-of-function MDA5 variants cause recurrent infections (Lamborn *et al*, 2017), and have been reported to contribute to inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease (Adiliaghdam *et al*, 2022; Cananzi *et al*, 2021). GWAS data have also associated loss-of-function MDA5 variants with reduced risk of developing certain autoimmune diseases, most notably T1D (Downes *et al*, 2010; Gorman *et al*, 2017; Liu *et al*, 2009; Nejentsev *et al*, 2009; Smyth *et al*, 2006; Vasseur *et al*, 2011). Specifically, variants E627* (rs35744605), R843H (rs3747517), I923V (rs35667974), and T946A (rs1990760) have been identified as T1D-protective (de Azevedo Silva *et al*, 2015; Gorman *et al*., 2017; Jermendy *et al*, 2018; Liu *et al*., 2009; Nejentsev *et al*., 2009; Smyth *et al*., 2006; Vasseur *et al*., 2011). The E627* and I923V variants are rare, with allele frequencies of 1-2%, while R843H and T946A are common. These common variants are differentially expressed in different geographic populations. The T946A variant is present in 70-80% of Africans and Asians but only 30-50% of Caucasians (de Azevedo Silva *et al*., 2015; Gorman *et al*., 2017; Liu *et al*., 2009; Nejentsev *et al*., 2009; Vasseur *et al*., 2011). Similarly, the R843H variant is found in 70% of Asians but only 30-40% of Caucasians and Africans (de Azevedo Silva *et al*., 2015; Gorman *et al*., 2017; Liu *et al*., 2009; Nejentsev *et al*., 2009; Vasseur *et al*., 2011). Most human *IFIH1* reference sequences contain the alleles that are most common in Asians (Ala946/His843). These coding variants inhibit the formation of MDA5-dsRNA signaling complexes (Gorman *et al*., 2017; Shigemoto *et al*, 2009) by reducing the RNA binding affinity of MDA5 or hyperactivating its ATPase activity (Singh *et al*, 2024a). Other loss-of-function variants are splice donor variants that reduce splicing efficiency and hence mRNA levels (Downes *et al*., 2010).

61 A robust clinical link has emerged between T1D onset and recent infection with RNA viruses, in
62 particular coxsackieviruses and other enteroviruses (Yeung *et al*, 2011). T1D patients have more frequent
63 and persistent enterovirus infections, which precede the appearance of prediabetic markers, including
64 autoantibodies (Hyoty & Taylor, 2002). MDA5 recognizes RNA from *Picornaviridae*, including
65 enteroviruses (Kato *et al*., 2006; Wang *et al*, 2010), which have evolved mechanisms to suppress IFN-β
66 transcription (Hato *et al*, 2007; Visser *et al*, 2019). MDA5-induced inflammation in the pancreas
67 following rotavirus infection contributes to autoimmune destruction of pancreatic β-cells (Dou *et al*,
68 2017). Therefore, a plausible hypothesis is that MDA5-dependent inflammation following viral infection
69 can trigger autoimmune β-cell killing.

70 Gastrointestinal viral infection has also been linked to IBD onset(Axelrad *et al*, 2019). Intestinal
71 cells from IBD patients harboring loss-of-function MDA5 variants had elevated viral loads and were
72 compromised in their ability to maintain epithelial barrier integrity upon further exposure to the enteric
73 virome (Adiliaghdam *et al*., 2022). Hence, the frequency and clinical phenotypes of MDA5 loss-of-
74 function variants in IBD patients suggest that MDA5 deficiency contributes to the induction of IBD
75 (Adiliaghdam *et al*., 2022; Cananzi *et al*., 2021), due in part to increased exposure and susceptibility to
76 viral infection (Adiliaghdam *et al*., 2022; Lamborn *et al*., 2017).

77 **Results and discussion**

78 Loss-of-function MDA5 variants have been associated with recurrent infection (Lamborn *et al*., 2017),
79 T1D protection (Downes *et al*., 2010; Gorman *et al*., 2017; Liu *et al*., 2009; Nejentsev *et al*., 2009; Smyth
80 *et al*., 2006; Vasseur *et al*., 2011), and IBD risk (Adiliaghdam *et al*., 2022; Cananzi *et al*., 2021).
81 However, whether these associations are linked, or whether they apply to autoimmune disease more
82 broadly, has not been explored. We addressed these questions by utilizing larger, more recent GWAS
83 studies to conduct a broader, more sensitive survey of immune-mediated disease associations involving
84 MDA5 variants. For our analysis, we selected GWAS datasets to maximize the likelihood of accurate fine

85 mapping – balancing the need for large sample size, minimizing the use of imputed genotypes, and using
86 ancestries that best matched the reference panel used to derive linkage disequilibrium (LD) estimates
87 (Karczewski *et al*, 2024; Liu *et al*, 2015; Robertson *et al*, 2021; Tsoi *et al*, 2017) (see **Materials and**
88 **methods**). By reviewing associations with a reported lead T1D-associated variant, I923V (rs35667974)
89 (Nejentsev *et al*., 2009) we identified psoriasis, hypothyroidism, Crohn's disease, and ulcerative colitis as
90 additional associated diseases. Fine-mapping analysis using GWAS summary data for these five diseases
91 identified four variants likely to be causally associated with a subset of the diseases, with considerable
92 overlap of variants between diseases (**Fig. 1, Table I**). Two of these variants were coding variants, I923V
93 and T946A, and two were splice donor variants, rs35337543 and rs35732034. All four variants were
94 previously associated with T1D protection (Downes *et al*., 2010; Gorman *et al*., 2017; Liu *et al*., 2009;
95 Nejentsev *et al*., 2009; Smyth *et al*., 2006; Vasseur *et al*., 2011).

96 Given the overlaps between diseases, and the small *P* values observed for fine-mapped variants in
97 one disease when considering another, we called associated variants by considering marginal association
98 at any of these variants or other known loss-of-function variants not in LD with any of the index variants
99 using a stringent Bonferroni correction. This identified associations of a fifth variant, E627*
100 (rs35744605), with psoriasis, and hypothyroidism (**Fig. 1**). While T946A is common, the other variants
101 are rare (allele frequency below 3%). Fine-mapping analysis did not find evidence for causality for
102 variants E627* and R843H (**Table I**). However, for E627* the lack of evidence of causality is likely due
103 to its low allele frequency (0.7%), which limits power in genetics studies. In contrast, association of
104 R843H with T1D protection is likely attributable to LD with the co-occurring causal T946A allele (r^2 =
105 0.60), as previously reported (Gorman *et al*., 2017; Liu *et al*., 2009; Nejentsev *et al*., 2009). Supporting
106 these conclusions, our accompanying biochemical and structural study of T1D-protective MDA5 variants
107 shows that the E627* variant lacks signaling activity due to a loss of RNA binding affinity, whereas the
108 R843H substitution had no effect on the structural, biochemical or signaling activities of MDA5 (Singh *et*
109 *al*., 2024a).

110 Comparing associations across diseases, we found that all five associated variants offered
111 protection against T1D, psoriasis and hypothyroidism, but increased the risk of ulcerative colitis and
112 Crohn's disease (**Fig. 2a**). Remarkably, a strict correlation was observed between protection and risk
113 (**Fig. 2b**). A statistical test of proportionality (see **Materials and methods**) concluded that changes in risk
114 were linearly proportional across variants (**Fig. 2c**). Additionally, the magnitudes of the odds ratios were
115 larger for the rare variants than for the common variants. Thus, the rarest variant, I923V, conferred the
116 greatest degree of T1D protection and the greatest risk of IBD, whereas the most common variant,
117 T946A, was associated with the least T1D protection and IBD risk (**Fig. 2a-b**). Notably, the T946A
118 variant, while common in all populations, is the major allele in Asian and African populations but the
119 minor allele in Caucasians.

120 Our GWAS meta-analysis uncovers a direct correlation between protection from autoimmune-
121 related diseases (T1D, psoriasis and hypothyroidism) and increased risk of IBD. The implication is that
122 calibration of MDA5-dependent antiviral signaling offers a fundamental fitness trade-off. Loss-of-
123 function MDA5 variants protect from autoimmune tissue damage, including to pancreatic β-cells leading
124 to T1D, but increase the risk of inflammatory tissue damage from persistent infection, including by
125 enteric viruses in intestinal epithelia leading to IBD. This model predicts that gain-of-function MDA5
126 variants protect from chronic inflammation and IBD by ensuring infections are cleared but do so at the
127 cost of increasing the risk of T1D and other autoimmune diseases.

128 **Materials and methods**

129 **GWAS meta-analysis**

130 GWAS summary data for a reported lead T1D-associated variant, I923V (rs35667974) were downloaded
131 for the following diseases: T1D (16,000 T1D cases, 25,000 controls) (Robertson *et al*., 2021); IBD (5,956
132 Crohn's disease cases, 6,968 ulcerative colitis cases, 21,770 controls) (Liu *et al*., 2015); psoriasis (19,032
133 cases, 286,769 controls) (Tsoi *et al*., 2017); and hypothyroidism (20,563 cases, 399,910 controls)

134 (Karczewski *et al*., 2024). Data were downloaded from the GWAS catalog from the following
135 repositories: ulcerative colitis, https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001-
136 GCST004000/GCST003045/harmonised/26192919-GCST003045-EFO_0000729.h.tsv.gz
137 (ImmunoChip); Crohn's disease,
138 https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST003001-
139 GCST004000/GCST003044/harmonised/26192919-GCST003044-EFO_0000384.h.tsv.gz
140 (ImmunoChip); T1D, https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90013001-
141 GCST90014000/GCST90013445/GCST90013445_buildGRCh38.tsv (ImmunoChip); Psoriasis:
142 http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST005001-
143 GCST006000/GCST005527/harmonised/23143594-GCST005527-EFO_0000676.h.tsv.gz (Meta
144 analysis); Hypothyroidism: https://pan-ukb-us-east-1.s3.amazonaws.com/sumstats_flat_files/categorical-
145 20002-both_sexes-1453.tsv.bgz (genome wide SNP chip). These studies were selected to balance the
146 need for large studies and those most likely to give accurate results in fine mapping – i.e. those which
147 minimized imputation and most closely matched the ancestry of our reference LD panel.
148 Alleles were aligned to the UK Biobank as a common reference. Reference LD matrices were
149 estimated from 40,000 European subjects from UK Biobank. Fine mapping was performed with a variant
150 of the Sum of Single Effects (SuSiE) (Wang *et al*, 2020) model, as implemented in susieR (Zou *et al*,
151 2022).
152 rs72871627 was selected as a tag ($r^2 = 0.99$) of the splice donor variant rs35337543 because
153 rs72871627 was available in all GWAS datasets whereas rs35337543 was only available in the T1D
154 GWAS dataset.
155 Tests of proportional effects between pairs of diseases were performed across all variants in Table I
156 using colocPropTest [https://cran.r-project.org/package=colocPropTest] which implements the test of
157 proportionality as previously described (Wallace, 2013).

158 **Data Availability**

159 This study is a meta-analysis of previously published data. All code to reproduce this analysis is available
160 at Zenodo.org [https://doi.org/10.5281/zenodo.12771481].

161 **Competing Interests**

162 Y.M. is a consultant for Related Sciences LLC. C.E.W. is a part time employee at GSK. GSK was not
163 involved in this study. R.S. has no competing interests or conflicts to declare.

164 **Author Contributions**

165 Conceptualization, C.E.W., R.S. and Y.M.; Methodology, C.E.W.; Formal Analysis, C.E.W. and Y.M.;
166 Funding Acquisition, Y.M.; Project Administration, Y.M.; Software, C.E.W.; Supervision, Y.M.; Writing
167 – Original Draft, Y.M.; Writing – Review & Editing, C.E.W., R.S. and Y.M.

168 **Acknowledgements**

169 We thank Louise Modis, Tetsuo Hasegawa, and the Modis group for useful discussions. This work was
170 supported by the Wellcome Trust [217191/Z/19/Z to Y.M.] and [WT220788 to C.E.W], and the Medical
171 Research Council [MC_UU_00040/01 to C.E.W.].

172

173 **References**

174 Adiliaghdam F, Amatullah H, Digumarthi S, Saunders TL, Rahman RU, Wong LP, Sadreyev R, Droit L,
175 Paquette J, Goyette P *et al* (2022) Human enteric viruses autonomously shape inflammatory bowel
176 disease phenotype through divergent innate immunomodulation. *Sci Immunol* 7: eabn6660

177 Axelrad JE, Olen O, Askling J, Lebwohl B, Khalili H, Sachs MC, Ludvigsson JF (2019) Gastrointestinal
178 Infection Increases Odds of Inflammatory Bowel Disease in a Nationwide Case-Control Study. *Clin*
179 *Gastroenterol Hepatol* 17: 1311-1322 e1317

180 Berke IC, Modis Y (2012) MDA5 cooperatively forms dimers and ATP-sensitive filaments upon binding
181 double-stranded RNA. *EMBO J* 31: 1714-1726

182 Cananzi M, Wohler E, Marzollo A, Colavito D, You J, Jing H, Bresolin S, Gaio P, Martin R, Mescoli C *et*
183 *al* (2021) IFIH1 loss-of-function variants contribute to very early-onset inflammatory bowel disease.
184 *Hum Genet* 140: 1299-1312
185 de Azevedo Silva J, Tavares NA, Santos MM, Moura R, Guimaraes RL, Araujo J, Crovella S, Brandao
186 LA (2015) Meta-analysis of STAT4 and IFIH1 polymorphisms in type 1 diabetes mellitus patients
187 with autoimmune polyglandular syndrome type III. *Genet Mol Res* 14: 17730-17738
188 Dou Y, Yim HC, Kirkwood CD, Williams BR, Sadler AJ (2017) The innate immune receptor MDA5
189 limits rotavirus infection but promotes cell death and pancreatic inflammation. *EMBO J* 36: 2742-
190 2757
191 Downes K, Pekalski M, Angus KL, Hardy M, Nutland S, Smyth DJ, Walker NM, Wallace C, Todd JA
192 (2010) Reduced expression of IFIH1 is protective for type 1 diabetes. *PLoS One* 5
193 Garau J, Cavallera V, Valente M, Tonduti D, Sproviero D, Zucca S, Battaglia D, Battini R, Bertini E,
194 Cappanera S *et al* (2019) Molecular Genetics and Interferon Signature in the Italian Aicardi Goutieres
195 Syndrome Cohort: Report of 12 New Cases and Literature Review. *J Clin Med* 8: 750
196 Gorman JA, Hundhausen C, Errett JS, Stone AE, Allenspach EJ, Ge Y, Arkatkar T, Clough C, Dai X,
197 Khim S *et al* (2017) The A946T variant of the RNA sensor IFIH1 mediates an interferon program that
198 limits viral infection but increases the risk for autoimmunity. *Nat Immunol* 18: 744-752
199 Hato SV, Ricour C, Schulte BM, Lanke KH, de Bruijni M, Zoll J, Melchers WJ, Michiels T, van
200 Kuppeveld FJ (2007) The mengovirus leader protein blocks interferon-alpha/beta gene transcription
201 and inhibits activation of interferon regulatory factor 3. *Cell Microbiol* 9: 2921-2930
202 Hyoty H, Taylor KW (2002) The role of viruses in human diabetes. *Diabetologia* 45: 1353-1361
203 Jermendy A, Szatmari I, Korner A, Szabo AJ, Toth-Heyn P, Hermann R (2018) Association between
204 interferon-induced helicase (IFIH1) rs1990760 polymorphism and seasonal variation in the onset of
205 type 1 diabetes mellitus. *Pediatr Diabetes* 19: 300-304

206 Karczewski KJ, Gupta R, Kanai M, Lu W, Tsuo K, Wang Y, Walters RK, Turley P, Callier S, Baya N *et*
207 *al* (2024) Pan-UK Biobank GWAS improves discovery, analysis of genetic architecture, and
208 resolution into ancestry-enriched effects. *bioRxiv*: 2024.2003.2013.24303864
209 Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii
210 KJ *et al* (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.
211 *Nature* 441: 101-105
212 Lamborn IT, Jing H, Zhang Y, Drutman SB, Abbott JK, Munir S, Bade S, Murdock HM, Santos CP,
213 Brock LG *et al* (2017) Recurrent rhinovirus infections in a child with inherited MDA5 deficiency. *J*
214 *Exp Med* 214: 1949-1972
215 Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T
216 *et al* (2015) Association analyses identify 38 susceptibility loci for inflammatory bowel disease and
217 highlight shared genetic risk across populations. *Nat Genet* 47: 979-986
218 Liu S, Wang H, Jin Y, Podolsky R, Reddy MV, Pedersen J, Bode B, Reed J, Steed D, Anderson S *et al*
219 (2009) IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene
220 expression in peripheral blood mononuclear cells. *Hum Mol Genet* 18: 358-365
221 Nejentsev S, Walker N, Riches D, Egholm M, Todd JA (2009) Rare variants of IFIH1, a gene implicated
222 in antiviral responses, protect against type 1 diabetes. *Science* 324: 387-389
223 Peisley A, Lin C, Wu B, Orme-Johnson M, Liu M, Walz T, Hur S (2011) Cooperative assembly and
224 dynamic disassembly of MDA5 filaments for viral dsRNA recognition. *Proc Natl Acad Sci U S A* 108:
225 21010-21015
226 Rice GI, Park S, Gavazzi F, Adang LA, Ayuk LA, Van Eyck L, Seabra L, Barrea C, Battini R, Belot A *et*
227 *al* (2020) Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. *Hum Mutat* 41:
228 837-849
229 Robertson CC, Inshaw JRJ, Onengut-Gumuscu S, Chen WM, Santa Cruz DF, Yang H, Cutler AJ, Crouch
230 DJM, Farber E, Bridges SL, Jr. *et al* (2021) Fine-mapping, trans-ancestral and genomic analyses
231 identify causal variants, cells, genes and drug targets for type 1 diabetes. *Nat Genet* 53: 962-971

232 Rodero MP, Crow YJ (2016) Type I interferon-mediated monogenic autoinflammation: The type I
233 interferonopathies, a conceptual overview. *J Exp Med* 213: 2527-2538
234 Rutsch F, MacDougall M, Lu C, Buers I, Mamaeva O, Nitschke Y, Rice GI, Erlandsen H, Kehl HG,
235 Thiele H *et al* (2015) A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome.
236 *Am J Hum Genet* 96: 275-282
237 Shigemoto T, Kageyama M, Hirai R, Zheng J, Yoneyama M, Fujita T (2009) Identification of loss of
238 function mutations in human genes encoding RIG-I and MDA5: implications for resistance to type I
239 diabetes. *J Biol Chem* 284: 13348-13354
240 Singh R, Herrero Del Valle A, Joiner J, Zwaagstra M, Ferguson BJ, Kuppeveld FJM, Modis Y (2024a)
241 Molecular basis of pathogenesis and protection from type 1 diabetes by loss of function MDA5
242 variants. bioR*xiv*: *2024.10.03.616466*
243 Singh R, Wu Y, Herrero Del Valle A, Leigh KE, Mong S, Cheng MTK, Ferguson BJ, Modis Y (2024b)
244 Contrasting functions of ATP hydrolysis by MDA5 and LGP2 in viral RNA sensing. *J Biol Chem* 300:
245 105711
246 Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, Guja C, Ionescu-Tirgoviste C, Widmer B,
247 Dunger DB *et al* (2006) A genome-wide association study of nonsynonymous SNPs identifies a type 1
248 diabetes locus in the interferon-induced helicase (IFIH1) region. *Nat Genet* 38: 617-619
249 Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, Ellinghaus E, Barker JN, Chandran
250 V, Dand N *et al* (2017) Large scale meta-analysis characterizes genetic architecture for common
251 psoriasis associated variants. *Nat Commun* 8: 15382
252 Vasseur E, Patin E, Laval G, Pajon S, Fornarino S, Crouau-Roy B, Quintana-Murci L (2011) The
253 selective footprints of viral pressures at the human RIG-I-like receptor family. *Hum Mol Genet* 20:
254 4462-4474
255 Visser LJ, Langereis MA, Rabouw HH, Wahedi M, Muntjewerff EM, de Groot RJ, van Kuppeveld FJM
256 (2019) Essential Role of Enterovirus 2A Protease in Counteracting Stress Granule Formation and the
257 Induction of Type I Interferon. *J Virol* 93

258 Wallace C (2013) Statistical testing of shared genetic control for potentially related traits. *Genet*
259 *Epidemiol* 37: 802-813
260 Wang G, Sarkar A, Carbonetto P, Stephens M (2020) A simple new approach to variable selection in
261 regression, with application to genetic fine mapping. *J R Stat Soc Series B Stat Methodol* 82: 1273-
262 1300
263 Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW (2010) MDA5 and MAVS
264 mediate type I interferon responses to coxsackie B virus. *J Virol* 84: 254-260
265 Yeung WC, Rawlinson WD, Craig ME (2011) Enterovirus infection and type 1 diabetes mellitus:
266 systematic review and meta-analysis of observational molecular studies. *BMJ* 342: d35
267 Yu Q, Herrero Del Valle A, Singh R, Modis Y (2021) MDA5 disease variant M854K prevents ATP-
268 dependent structural discrimination of viral and cellular RNA. *Nat Commun* 12: 6668
269 Yu Q, Qu K, Modis Y (2018) Cryo-EM Structures of MDA5-dsRNA Filaments at Different Stages of
270 ATP Hydrolysis. *Mol Cell* 72: 999-1012 e1016
271 Zou Y, Carbonetto P, Wang G, Stephens M (2022) Fine-mapping from summary data with the "Sum of
272 Single Effects" model. *PLoS genetics* 18: e1010299
273
274



SNP	MAF	description
T946A	0.3892	loss of function
I923V	0.0216	loss of function
rs35732034	0.0097	splice donor
rs35337543	0.0153	splice donor
rs72871627	0.0147	r2=0.99 with rs35337543

Fig. 1. Manhattan plots of fine-mapped variants for five diseases. Colored circles indicate the fine mapping sets identified, and colored text labels the most likely causal SNP in each set, selected due its known function on MDA5. Known loss-of-function SNPs that were not in any fine mapping set are marked with "x" and a black label. Lower right, minor allele frequency (MAF) and function of fine-mapped SNPs.



Figure 2. GWAS meta-analysis of loss-of-function MDA5 variants. (a) Effect sizes expressed in terms of the odd ratio for selected MDA5 loss-of-function variants. ‡Because rs35337543 was only available in two GWAS datasets, rs72871627 ($r^2 = 0.973$) was used as a tag for rs35337543. EAF, effect allele frequency. Error bars, SEM. ns, $P > 0.05$; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 5\times10^{-8}$ (genome-wide significance), where P is the Bonferroni-adjusted P value from marginal association analysis. CV, likely causal variant present in a credible set in fine-mapping analysis. R843H was included in fine-mapping analysis but excluded from marginal association analysis. See **Table I**. **(b)** Odds ratio plot for variants and diseases in *(a)*. **(c)** Estimated effect sizes in hypothyroidism compared to the other diseases. Hypothyroidism was selected because it was the largest dataset for which all SNPs were available. Dashed lines, identity and negative identity lines.

292 **Table I. Marginal association and fine-mapping analysis results.**

Variant	SNP	Location	Allele	EAF	Disease	lnOR ± std. err.	OR	P	$P_{Bonferroni}$	Causal‡
I923V	rs35667974	2:162268127	T>C	0.022	T1D	-0.493 ± 0.062	0.611	1.21×10^{-15}	2.91×10^{-14}	T
					Psoriasis	-0.440 ± 0.129	0.644	6.68×10^{-4}	0.0160	F
					Hypothyr.	-0.254 ± 0.038	0.776	2.98×10^{-11}	7.16×10^{-10}	T
					Crohn's	0.121 ± 0.046	1.129	8.08×10^{-3}	0.1938	F
					UC	0.276 ± 0.046	1.318	1.94×10^{-9}	4.64×10^{-8}	T
Splice1	rs35732034	2:162268086	C>T	0.010	Psoriasis	-0.693 ± 0.253	0.500	6.25×10^{-3}	0.1500	F
					T1D	-0.464 ± 0.083	0.629	2.29×10^{-8}	5.50×10^{-7}	T
					Hypothyr.	-0.230 ± 0.056	0.794	4.47×10^{-5}	1.07×10^{-3}	F
					UC	0.180 ± 0.067	1.197	7.70×10^{-3}	0.1848	F
					Crohn's	0.226 ± 0.064	1.253	4.15×10^{-4}	9.96×10^{-3}	F
Splice2*	rs72871627	2:162280432	A>G	0.015	Psoriasis	-0.541 ± 0.200	0.582	6.81×10^{-3}	0.1634	F
					T1D	-0.458 ± 0.073	0.633	4.19×10^{-10}	1.00×10^{-8}	T
					Hypothyr.	-0.253 ± 0.046	0.777	2.94×10^{-8}	7.05×10^{-7}	T
					Crohn's	0.072 ± 0.056	1.074	0.1990	1	F
					UC	0.308 ± 0.054	1.360	1.19×10^{-8}	2.85×10^{-7}	T
Splice2	rs35337543	2:162279995	C>G	0.015	T1D	-0.458 ± 0.073	0.633	4.19×10^{-10}	ND	T
					Hypothyr.	-0.236 ± 0.045	0.790	1.51×10^{-7}	ND	T
E627*	rs35744605	2:162277580	C>A	0.007	Hypothyr.	-0.273 ± 0.068	0.761	5.63×10^{-5}	1.35×10^{-3}	F
					Psoriasis	-0.210 ± 0.372	0.810	0.5717	1	F
T946A	rs1990760	2:162267541	T>C	0.389	Psoriasis	-0.192 ± 0.034	0.825	1.95×10^{-8}	4.68×10^{-7}	T
					T1D	-0.132 ± 0.013	0.876	5.57×10^{-24}	1.34×10^{-22}	T
					Hypothyr.	-0.080 ± 0.011	0.923	5.61×10^{-13}	1.35×10^{-11}	T
					Crohn's	0.053 ± 0.013	1.055	3.36×10^{-5}	8.07×10^{-4}	F
					UC	0.086 ± 0.013	1.089	1.78×10^{-10}	4.27×10^{-9}	T
R843H	rs3747517	2:162272314	C>T	0.276	T1D	-0.111 ± 0.014	0.895	2.94×10^{-15}	ND	F
					Psoriasis	-0.103 ± 0.035	0.903	3.72×10^{-3}	ND	F
					Hypothyr.	-0.068 ± 0.012	0.934	1.85×10^{-8}	ND	F
					Crohn's	0.030 ± 0.014	1.031	0.0301	ND	F
					UC	0.051 ± 0.014	1.053	3.85×10^{-4}	ND	F
N160D	rs74162075	2-162310909	T>C	0.001	Psoriasis	-2.057 ± 0.811	0.128	0.0111	0.2674	F
					Hypothyr.	-0.270 ± 0.133	0.763	0.0427	1	F

293 EAF, effect allele frequency; OR, odds ratio.
294 *rs72871627 was used as a tag of rs35337543 because the latter was not available in all GWAS datasets.
295 ‡Causality was inferred from presence of the SNP in a credible set in fine mapping analysis.
296 Dashed lines indicate that the SNPs above and below the line are in LD with each other.